Danvatirsen sodium is under clinical development by AstraZeneca and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Danvatirsen sodium’s likelihood of approval (LoA) and phase transition for Non-Small Cell Lung Cancer took place on 06 Jun 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Danvatirsen sodium Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Danvatirsen sodium overview

Danvatirsen sodium (IONIS-STAT3) is under development for the treatment of recurrent and metastatic head and neck cancer squamous cell carcinoma, advanced solid malignancies, pancreatic cancer, non-small cell lung cancer, colorectal cancer. It is administered through intravenous route. The drug candidate is a 16 oligonucleotide antisense molecule (ASO) targeting the 3' untranslated part of signal transducer and activator of transcription 3 (STAT3). It is based on FLAME discovery engine. It was also under development for the treatment of metastatic hepatocellular carcinoma, gastrointestinal cancer, ovarian cancer, malignant ascites and diffuse large B-Cell lymphoma. It is being developed based on FLAME (Flamingo Long non-coding RNA (LncRNA) Antisense Mining Engine) technology platform.

AstraZeneca overview

AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The COVID-19 Vaccine AstraZeneca has been approved for conditional marketing or emergency use. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.

Quick View Danvatirsen sodium LOA Data

Report Segments
  • Innovator
Drug Name
  • Danvatirsen sodium
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: AstraZeneca
  • Originator: Ionis Pharmaceuticals
Highest Development Stage
  • Phase II


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.